PORTEFEUILLE

Immunotherapy has transformed cancer treatment—but today, most patients receive these expensive therapies without knowing whether they will respond. EVIIVE is developing a predictive blood test that uses single-vesicle profiling of extracellular vesicles (EVs) to decode immune response signals in cancer patients. Our solution combines a standardized lab kit with a machine learning software platform to deliver clinically actionable predictions from a simple blood sample. By guiding immunotherapy decisions before treatment begins, EVIIVE has the potential to reduce costs, spare patients from ineffective therapies, and increase success rates in clinical trials. The technology is protected by a novel biomarker strategy and is being validated in collaboration with leading Swiss hospitals and global pharma partners.

The project set out to develop a clinically viable diagnostic platform for immunotherapy response prediction, using signals found in patient blood samples. In the first phase, we completed technical and analytical validation in a retrospective melanoma cohort and secured access to over 200 biobanked clinical samples through academic partnerships. We also initiated a strategic collaboration with an oncology biotech company to test our biomarker concept in an independent indication.
Key interim goals—such as cohort access, biomarker proof-of-concept, and data readiness—have been achieved. The project closes a critical gap in the oncology care pathway by offering a scalable method to guide treatment decisions before costly or ineffective immunotherapies are initiated. A spin-off company, EVIIVE AG, has been founded to implement and commercialize the results.
We are in active discussions with academic centers (e.g., USZ and Aarau Kantonsspital) for early clinical adoption and with diagnostic and pharma industry partners (e.g., Roche Diagnostics, Merck, and Eli Lilly) for broader deployment. The project has secured follow-up funding through Venture Kick (CHF 150,000), and Kickfund (CHF 100,000), with a seed financing round currently underway.